anti romo1 Search Results


romo1 antibody (oti2c12)  (Bio-Techne corporation)
90
Bio-Techne corporation romo1 antibody (oti2c12)
Romo1 Antibody (Oti2c12), supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+romo1/ROMO1+Antibody+(OTI2C12)/bio-techne+corporation___nbp2-45607
Average 90 stars, based on 1 article reviews
romo1 antibody (oti2c12) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
romo1  (Atlas Antibodies)
92
Atlas Antibodies romo1
Figure 3. Effect of anti-PLA2R serum on podocyte phenotype. (A and B) C3aR (A) and PLA2R1 (B) RNA expression in podocytes exposed to 0.5% healthy or MN serum for 72 hours. Red dotted line: hPOD in media with no serum, normalization group (n = 3/group). (C) Western Blotting bands for C3aR (54kDa) and PLA2R1 (150 kDa) and respective beta actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (D) Western blotting analysis of C3aR (54kDa) in hPOD monolayers exposed to MN sera, confirming an increased expression after 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression. n = 3/group. (E) Western blotting analysis of PLA2R (150 kDa) in hPOD monolayers exposed to MN sera, showing a statis- tically significant increase in protein expression at 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression (n = 3/group). (F) Western Blotting bands for <t>ROMO1</t> (10 kDa) and caspase-3 (35 kDa) and respective β-actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (G) Western blotting analysis of oxidative stress, measured by expression of ROMO1 (10 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing a significantly increased protein level (n = 3/group). (H) Western blotting analysis of apoptosis, measured by expression of caspase-3 (35 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing an increased expression (n = 3/group). (I and J) hPOD monolayers exposed to healthy (I) or MN serum (J) confirmed an increase in ROMO1 (red). DAPI, blue. Scale bar: 25 µm. (K and L) Representative immunofluorescence staining of hPOD monolayers exposed to healthy (K) or MN serum (L) confirmed an increase in caspase-3 (red). DAPI, blue. Scale bar: 25 µm. All statistical values determined by 2-tailed Student’s t test. *P < 0.05, **P < 0.01.
Romo1, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+romo1/Anti-ROMO1/pm38227377-181-20-29
Average 92 stars, based on 1 article reviews
romo1 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
rabbit anti-human romo1 polyclonal antibody  (Cusabio)
N/A
Rabbit anti-Human ROMO1 Polyclonal Antibody
   Buy from Supplier
anti-romo1 (aa 49-79) polyclonal antibody  (Creative BioMart)
N/A
Induces production of reactive oxygen species (ROS) which are necessary for cell proliferation. May play a role in inducing oxidative DNA damage and replicative senescence.Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid
   Buy from Supplier
anti-romo1 mouse monoclonal antibody  (Boster Bio)
N/A
Boster Bio ROMO1 mouse monoclonal antibody, clone OTI2C12 (formerly 2C12). Catalog# M05468. Tested in IF, IHC, WB. This antibody reacts with Human, Mouse, Rat.
   Buy from Supplier

Image Search Results


Figure 3. Effect of anti-PLA2R serum on podocyte phenotype. (A and B) C3aR (A) and PLA2R1 (B) RNA expression in podocytes exposed to 0.5% healthy or MN serum for 72 hours. Red dotted line: hPOD in media with no serum, normalization group (n = 3/group). (C) Western Blotting bands for C3aR (54kDa) and PLA2R1 (150 kDa) and respective beta actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (D) Western blotting analysis of C3aR (54kDa) in hPOD monolayers exposed to MN sera, confirming an increased expression after 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression. n = 3/group. (E) Western blotting analysis of PLA2R (150 kDa) in hPOD monolayers exposed to MN sera, showing a statis- tically significant increase in protein expression at 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression (n = 3/group). (F) Western Blotting bands for ROMO1 (10 kDa) and caspase-3 (35 kDa) and respective β-actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (G) Western blotting analysis of oxidative stress, measured by expression of ROMO1 (10 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing a significantly increased protein level (n = 3/group). (H) Western blotting analysis of apoptosis, measured by expression of caspase-3 (35 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing an increased expression (n = 3/group). (I and J) hPOD monolayers exposed to healthy (I) or MN serum (J) confirmed an increase in ROMO1 (red). DAPI, blue. Scale bar: 25 µm. (K and L) Representative immunofluorescence staining of hPOD monolayers exposed to healthy (K) or MN serum (L) confirmed an increase in caspase-3 (red). DAPI, blue. Scale bar: 25 µm. All statistical values determined by 2-tailed Student’s t test. *P < 0.05, **P < 0.01.

Journal: JCI insight

Article Title: C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy.

doi: 10.1172/jci.insight.172976

Figure Lengend Snippet: Figure 3. Effect of anti-PLA2R serum on podocyte phenotype. (A and B) C3aR (A) and PLA2R1 (B) RNA expression in podocytes exposed to 0.5% healthy or MN serum for 72 hours. Red dotted line: hPOD in media with no serum, normalization group (n = 3/group). (C) Western Blotting bands for C3aR (54kDa) and PLA2R1 (150 kDa) and respective beta actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (D) Western blotting analysis of C3aR (54kDa) in hPOD monolayers exposed to MN sera, confirming an increased expression after 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression. n = 3/group. (E) Western blotting analysis of PLA2R (150 kDa) in hPOD monolayers exposed to MN sera, showing a statis- tically significant increase in protein expression at 72 hours. Bands were normalized against β-actin (42 kDa), showing a significantly increased expression (n = 3/group). (F) Western Blotting bands for ROMO1 (10 kDa) and caspase-3 (35 kDa) and respective β-actin (42 kDa) exposed to healthy or anti-PLA2R serum (n = 3/group). (G) Western blotting analysis of oxidative stress, measured by expression of ROMO1 (10 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing a significantly increased protein level (n = 3/group). (H) Western blotting analysis of apoptosis, measured by expression of caspase-3 (35 kDa), in hPOD monolayers exposed to MN sera. Bands were normalized against β-actin (42 kDa), showing an increased expression (n = 3/group). (I and J) hPOD monolayers exposed to healthy (I) or MN serum (J) confirmed an increase in ROMO1 (red). DAPI, blue. Scale bar: 25 µm. (K and L) Representative immunofluorescence staining of hPOD monolayers exposed to healthy (K) or MN serum (L) confirmed an increase in caspase-3 (red). DAPI, blue. Scale bar: 25 µm. All statistical values determined by 2-tailed Student’s t test. *P < 0.05, **P < 0.01.

Article Snippet: The following primary antibodies were used: PLA2R (LS-C108906-100, LSBio), C3AR (NBP2-15649, NovusBio), caspase-3 (9662S, Cell Signaling Technology), Synaptopodin (ab224491, Abcam), ROMO1 (NBP2-45607, NovusBio), C5b-9 (bs-2673R, Bioss), and THSD7A (HPA000923, Atlas Antibodies).

Techniques: RNA Expression, Western Blot, Expressing, Immunofluorescence, Staining

Figure 4. C3aR antagonism effectively prevents changes in podocyte phenotype by MN serum. (A) Western blotting analysis of C3aR in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist efficient- ly prevented C3aR (54 kDa) increase. Bands were normalized against β-actin (42 KDa), showing a significantly decreased protein level. n = 3/group. (B) Western blotting analysis of PLA2R (150kDa) in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist efficiently prevented PLA2R increase. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. (C) Western blotting analysis of apoptosis, measured by expression of caspase-3 (35 kDa), in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist significantly decreased apoptosis in hPOD. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. (D) Western Blotting bands for Synaptopodin (100kDa) and ROMO1 (10 kDa) and respective β-actin (42 kDa) after exposure to healthy serum, anti-PLA2R serum, or anti-PLA2R serum + C3aRA. (n = 3/group). (E) Western blotting analysis of synaptopodin (100 kDa) in hPOD monolayers exposed to MN sera or MN sera+ C3aRA. The antagonist efficiently prevented synaptopodin loss. Bands were normalized against β-actin (42 kDa), showing a significantly increased protein level. Bands are shown in D. n of replicates/group: 3. (F) Western blotting analysis of oxidative stress, measured by expression of ROMO1 (10 kDa), in hPOD monolayers exposed to MN sera or MN sera+ C3aRA. The antagonist significantly decreased ROMO1 expression in hPOD. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. Bands are shown in D. All statistical values determined by 1-way ANOVA. *P < 0.05; **P < 0.01, ***P < 0.001.

Journal: JCI insight

Article Title: C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy.

doi: 10.1172/jci.insight.172976

Figure Lengend Snippet: Figure 4. C3aR antagonism effectively prevents changes in podocyte phenotype by MN serum. (A) Western blotting analysis of C3aR in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist efficient- ly prevented C3aR (54 kDa) increase. Bands were normalized against β-actin (42 KDa), showing a significantly decreased protein level. n = 3/group. (B) Western blotting analysis of PLA2R (150kDa) in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist efficiently prevented PLA2R increase. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. (C) Western blotting analysis of apoptosis, measured by expression of caspase-3 (35 kDa), in hPOD monolayers exposed to MN sera or MN sera + C3aRA. The antagonist significantly decreased apoptosis in hPOD. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. (D) Western Blotting bands for Synaptopodin (100kDa) and ROMO1 (10 kDa) and respective β-actin (42 kDa) after exposure to healthy serum, anti-PLA2R serum, or anti-PLA2R serum + C3aRA. (n = 3/group). (E) Western blotting analysis of synaptopodin (100 kDa) in hPOD monolayers exposed to MN sera or MN sera+ C3aRA. The antagonist efficiently prevented synaptopodin loss. Bands were normalized against β-actin (42 kDa), showing a significantly increased protein level. Bands are shown in D. n of replicates/group: 3. (F) Western blotting analysis of oxidative stress, measured by expression of ROMO1 (10 kDa), in hPOD monolayers exposed to MN sera or MN sera+ C3aRA. The antagonist significantly decreased ROMO1 expression in hPOD. Bands were normalized against β-actin (42 kDa), showing a significantly decreased protein level. n = 3/group. Bands are shown in D. All statistical values determined by 1-way ANOVA. *P < 0.05; **P < 0.01, ***P < 0.001.

Article Snippet: The following primary antibodies were used: PLA2R (LS-C108906-100, LSBio), C3AR (NBP2-15649, NovusBio), caspase-3 (9662S, Cell Signaling Technology), Synaptopodin (ab224491, Abcam), ROMO1 (NBP2-45607, NovusBio), C5b-9 (bs-2673R, Bioss), and THSD7A (HPA000923, Atlas Antibodies).

Techniques: Western Blot, Expressing